文献速递神经肿瘤功能神经外科

立体定向放射外科治疗肢端肥大症:国际多中心回顾性队列研究

Stereotactic Radiosurgery for Acromegaly: An International Multicenter Retrospective Cohort Study.
PubMed 文献 · Neurosurgery · 2019-01-01

该国际多中心回顾性队列研究纳入10家机构371例肢端肥大症患者,评估立体定向放射外科(SRS)的疗效与预测因素。10年初始和持久内分泌缓解率分别为69%和59%,持久缓解平均时间38个月。SRS前停用IGF-1降低药物是持久缓解的唯一独立预测因素(P=0.01)。

要点

  • SRS后10年初始内分泌缓解率为69%,持久缓解率为59%。
  • 持久缓解的平均时间为38个月,初始缓解后生化复发率为9%。
  • SRS前停用IGF-1降低药物是持久缓解的唯一独立预测因素(P=0.01)。

核心结论

  • SRS是手术切除后持续或复发性肢端肥大症的确定性治疗选择。
  • SRS前停用IGF-1降低药物与持久缓解之间似乎存在统计学关联。

研究设计与样本

  • 国际伽玛刀研究基金会10家参与机构的回顾性队列研究,纳入内分泌随访≥6个月的肢端肥大症患者。
  • 研究队列共371例患者,平均内分泌随访79个月。

主要发现

  • 56%的SRS前接受药物治疗的患者在SRS前停用了IGF-1降低药物。
  • 平均SRS治疗体积为3.0 cm3,边缘剂量为24.2 Gy。
  • 10年初始和持久内分泌缓解的 actuarial 率分别为69%和59%。
  • SRS后持久缓解的平均时间为38个月。
  • 初始缓解后生化复发率为9%,平均复发时间为17个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic radiosurgery (SRS) is a treatment option for persistent or recurrent acromegaly secondary to a growth hormone secreting pituitary adenoma, but its efficacy is inadequately defined. OBJECTIVE: To assess, in a multicenter, retrospective cohort study, the outcomes of SRS for acromegaly and determine predictors. METHODS: We pooled and analyzed data from 10 participating institutions of the International Gamma Knife Research Foundation for patients with acromegaly who underwent SRS with endocrine follow-up of ≥6 mo. RESULTS: The study cohort comprised 371 patients with a mean endocrine follow-up of 79 mo. IGF-1 lowering medications were held in 56% of patients who were on pre-SRS medical therapy. The mean SRS treatment volume and margin dose were 3.0 cm3 and 24.2 Gy, respectively. The actuarial rates of initial and durable endocrine remission at 10 yr were 69% and 59%, respectively. The mean time to durable remission after SRS was 38 mo. Biochemical relapse after initial remission occurred in 9%, with a mean time to recurrence of 17 mo. Cessation of IGF-1 lowering medication prior to SRS was the only independent predictor of durable remission (P = .01). Adverse radiation effects included the development of ≥1 new endocrinopathy in 26% and ≥1 cranial neuropathy in 4%. CONCLUSION: SRS is a definitive treatment option for patients with persistent or recurrent acromegaly after surgical resection. There appears to be a statistical association between the cessation of IGF-1 lowering medications prior to SRS and durable remission.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Ding D, Mehta GU, Patibandla MR, et al. Stereotactic Radiosurgery for Acromegaly: An International Multicenter Retrospective Cohort Study. Neurosurgery. 2019. PMID: 29757421. doi:10.1093/neuros/nyy178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。